CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and a tumor marker for anaplastic large cell lymphoma. From Wikipedia
An Innosuisse grant will let PSI’s radiopharmaceutical scientists refine a CD30-targeted terbium-161 therapy before initial human trials.
